Managing the risks of IBD therapy

Successful management of the patient with inflammatory bowel disease (IBD) involves not only the induction and maintenance of remission, but also the optimization of the benefit-to-risk equation to achieve the greatest gain in quality of life. These risks range from intolerance to prescribed medicat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current gastroenterology reports 2009-12, Vol.11 (6), p.509-517
Hauptverfasser:	Seow, Cynthia H., de Silva, Shanika, Kaplan, Gilaad G., Devlin, Shane M., Ghosh, Subrata, Panaccione, Remo
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Anti-Inflammatory Agents - adverse effects Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Gastroenterology Glucocorticoids - adverse effects Glucocorticoids - therapeutic use Humans Immunologic Factors - adverse effects Immunologic Factors - therapeutic use Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Inflammatory Bowel Diseases - drug therapy Medicine Medicine & Public Health Mesalamine - adverse effects Mesalamine - therapeutic use Risk Management Sulfasalazine - adverse effects Sulfasalazine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!